Prion-induced neuronal injury in vivo is associated with
prostaglandin E(2) production, a process that can be reproduced in tissue-culture models of
prion disease. In the present study, neuronal
phospholipase A(2) was activated by
glycosylphosphatidylinositols (GPIs) isolated from the cellular
prion protein (PrP(c)) or from disease-associated
isoforms (PrP(Sc)), resulting in
prostaglandin E(2) production, but not by GPIs isolated from Thy-1. The ability of GPIs to activate neuronal
phospholipase A(2) was lost following the removal of acyl chains or cleavage of the
phosphatidylinositol-glycan linkage, and was inhibited by a mAb that recognized
phosphatidylinositol. In competition assays, pretreatment of neurons with partial GPIs,
inositol monophosphate or
sialic acid reduced the production of
prostaglandin E(2) in response to a synthetic miniprion (sPrP106), a synthetic correlate of a PrP(Sc) species found in
Gerstmann-Straussler-Scheinker disease (HuPrP82-146),
prion preparations or high concentrations of PrP-GPIs. In addition, neurons treated with
inositol monophosphate or
sialic acid were resistant to the otherwise toxic effects of sPrP106, HuPrP82-146 or
prion preparations. This protective effect was selective, as
inositol monophosphate- or
sialic acid-treated neurons remained susceptible to the toxicity of
arachidonic acid or
platelet-activating factor. Addition of PrP-GPIs to cortical neuronal cultures increased
caspase-3 activity, a marker of apoptosis that is elevated in
prion diseases. In contrast, treatment of such cultures with
inositol monophosphate or
sialic acid greatly reduced sPrP106-induced
caspase-3 activity and, in co-cultures, reduced the killing of sPrP106-treated neurons by microglia. These results implicate
phospholipase A(2) activation by PrP-GPIs as an early event in
prion-induced neurodegeneration.